Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.
Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.
We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.
We have worked with many well-known companies on their biological products, including Pfizer, Novartis, Regeneron, Amgen and Roche.
News & insights
Publications: 07 OCTOBER 2021
Dealmaking across the globe continues to break records, as investors take advantage of benign market conditions to deploy capital at an accelerating pace.Read more
Publications: 06 OCTOBER 2021
How will recent legislative updates in Germany affect patent litigation?Read more
News: 21 SEPTEMBER 2021
Allen & Overy today announced that Dario de Martino has joined the firm as a partner in its M&A practice, based in New York. Dario joins from Morrison & Foerster LLP, where he was a partner in the M&A…Read more